Immunological responses and viral modulatory effects of vaccination with recombinant modified vaccinia virus Ankara (rMVA) expressing structural and regulatory transgenes of simian immunodeficiency virus (SIVmac32H/ J5M)

Journal of Medical Primatology

Volumn 36, Issue 2, 2007, Pages 80-94

  Berry, Neil ^a   Stebbings, R ^b   Brown, S ^a   Christian, P ^b   Thorstensson, R ^c   Ahmed, R K ^c   Davis, L ^a   Ferguson, D ^a   D'arcy, N ^a   Elsley, W ^a   Hull, R ^b   Lines, J ^b   Wade Evans, A ^a   Stott, J ^a   Almond, N ^a  

^a Potters Bar ^*  (United Kingdom)

^b NATIONAL INSTITUTE FOR BIOLOGICAL STANDARDS AND CONTROL   (United Kingdom)

^c Department for Immunology and Vaccinology   (United Kingdom)

Author keywords

Immune responses; rMVA; SIVmac; Vaccination; Viraemia

Indexed keywords

BETA CHEMOKINE; GAG PROTEIN; NEF PROTEIN; NEUTRALIZING ANTIBODY; POL PROTEIN; REV PROTEIN; SIMIAN IMMUNODEFICIENCY VIRUS VACCINE; TRANSACTIVATOR PROTEIN; VACCINIA VACCINE; VIRUS ENVELOPE PROTEIN; VIRUS VECTOR;

ANIMAL EXPERIMENT; ARTICLE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL STRAIN; CELLULAR IMMUNITY; CONTROLLED STUDY; DRUG EFFICACY; GENE EXPRESSION; HUMAN IMMUNODEFICIENCY VIRUS 1; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMORAL IMMUNITY; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGY; NONHUMAN; PRIORITY JOURNAL; SIMIAN IMMUNODEFICIENCY VIRUS; VIRAL GENE DELIVERY SYSTEM; VIREMIA; VIRUS REPLICATION;

SIMIAN IMMUNODEFICIENCY VIRUS; VACCINIA VIRUS ANKARA;

EID: 33947431954     PISSN: 00472565     EISSN: 16000684     Source Type: Journal    
DOI: 10.1111/j.1600-0684.2007.00216.x     Document Type: Article

References (51)

1. Ahmed R, Nilsson C, Wang Y, Lehner T, Biberfeld G, Thorstensson R: Β-Chemokine production in macaques vaccinated with live-attenuated virus correlates with protection against simian immunodeficiency virus (SIVsm) challenge. J Gen Virol 1999; 80:1569-74.
2. Ahmed RK, Nilsson C, Biberfeld G, Thorstensson R: Role of CD8+ cell-produced anti-viral factors in protective immunity in HIV-2-exposed but seronegative macaques resistant to intrarectal SIVsm challenge. Scand J Immunol 2001; 53:245-53.
3. Ahmed RK, Biberfeld G, Thorstensson R: Innate immunity in experimental SIV infection and vaccination. Mol Immunol 2005; 42:251-8 (review).
4. Allen TM, O'Connor DH, Jing P et al.: Tat-specific cytotoxic T lymphocytes select for SIV escape variants during resolution of primary viraemia. Nature 2000; 407:386-90.
5. Allen TM, Jing P, Calore B et al.: Effects of cytotoxic T lymphocytes (CTL) directed against a single simian immunodeficiency virus (SIV) Gag CTL epitope on the course of SIVmac239 infection. J Virol 2002; 76: 10507-11.
6. Almond N, Page M, Mills K, Jenkins A, Ling C, Thorpe R, Kitchin P, Williams M: The production and purification of PCR-derived recombinant simian immunodeficiency virus p27 gag protein; its use in detecting serological and T-cell responses in macaques. J Virol Methods 1990; 28: 305-19.
7. Almond N, Kent K, Cranage M, Rud E, Clarke B, Stott EJ: Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus infected cells. Lancet 1995; 345:1342-4.
8. van Baalen CA, Pontesilli O, Huisman RC, Geretti AM, Klein MR, de Wolf F, Miedema F, Gruters RA, Osterhaus AD: Human immunodeficiency virus type 1 Rev- and tat-specific cytotoxic T lymphocytes frequencies inversely correlate with rapid progression to AIDS. J Gen Virol 1997; 78:1913-8.
9. Barouch DH, Santra S, Schmitz JE et al.: Control of viraemia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science 2000; 290:486-92.
10. Barouch DH, Kunstman J, Kuroda MJ, Schmitz JE, Santra S, Peyerl FW, Krivulka GR, Beaudry K, Lifton MA, Gorgone DA, Montefiori DC, Lewis MG, Wolinsky SM, Letvin NL: Eventual AIDS vaccine failure in a rhesus monkey by viral escape from cytotoxic T lymphocytes. Nature 2002; 415:335-9.
11. Barouch DH, Kunstman J, Glowczwskie J, Kunstman KJ, Egan MA, Peyerl FW, Santra S, Kuroda MJ, Schmitz JE, Beaudry K, Krivulka GR, Lifton MA, Gorgone DA, Wolinsky SM, Letvin NL: Viral escape from dominant simian immunodeficiency virus epitope-specific cytotoxic T lymphocytes in DNA-vaccinated rhesus monkeys. J Virol 2003; 77:7367-75.
12. + cytotoxic T lymphocytes activity associated with control of viremia in primary human immunodeficiency virus type 1 infection. J Virol 1994; 68: 6103-10.
13. Cafaro A, Caputo A, Fracasso C, Maggiorella MT, Goletti D, Baroncelli S, Pace M, Sernicola L, Koanga-Mogtomo ML, Betti M, Borsetti A, Belli R, Akerblom L, Corrias F, Butto S, Heeney J, Verani P, Titti F, Ensoli B: Control of SHIV-89.6P-infection of cynomolgus monkeys by HIV-1 Tat protein vaccine. Nat Med 1999; 5:643-50.
14. Canto-Nogues C, Jones S et al.: In situ hybridization and immunolabelling study of the early replication of simian immunodeficiency virus (SIVmacJ5) in vivo. J Gen Virol 2001; 82:2225-34.
15. Casimiro DR, Chen L, Fu TM, Evans RK, Caulfield MJ et al.: Comparative immunogenicity in Rhesus monkeys of DNA plasmid, recombinant vaccinia vector ad replication defective adenovirus vectors expressing a human immunodeficiency virus type 1 gag gene. J Virol 2003; 77:6305-13.
16. Clarke S, Almond N, Berry N: Simian immunodeficiency virus Nef gene regulates the production of 2-LTR circles in vivo. Virology 2003; 306:100-8.
17. Cocchi F, DeVico AL, Yarchoan R, Redfield R, Cleghorn F, Blattner WA, Garzino-Demo A, Colombini-Hatch S, Margolis D, Gallo RC: Higher macrophage inflammatory protein (MIP)-1 α and MIP-1 β levels from CD8+ T cells are associated with asymptomatic HIV-1 infection. Proc Natl Acad Sci USA 2000; 97:13812-7.
18. Connor RI, Montefiori DC, Binley JM et al.: Temporal analysis of virus replication, immune responses and efficacy in rhesus macaques immunized with a live, attenuated simian immunodeficiency virus vaccine. J Virol 1998; 72:7501-9.
19. Cranage MP, Whatmore AM, Sharpe SA, Cook N, Polyanskaya N, Leech S, Smith JD, Rud EW, Dennis MJ, Hall GA: Macaques infected with live attenuated SIVmac are protected against superinfection via the rectal mucosa. Virology 1997; 229: 143-54.
20. Daniel MD, Kirchoff F, Czajak SC, Sehgal PK, Desrosiers RC: Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene. Science 1992; 258:1938-41.
21. Excler JL, Plotkin S: The prime boost concept applied to HIV preventative vaccines. AIDS 1997; 11 (Suppl. A): S127-37.
22. Gallimore A, Cranage M, Cook N, Almond N, Bootman J, Rud E, Silvera P, Dennis M, Corcoran T, Stott J et al.: Early suppression of SIV replication by CD8+ nef-specific cytotoxic T cells in vaccinated macaques. Nat Med 1995; 1:1167-73.
23. Geretti A-M, Hulskotte EJG, Dings M, van Baalen C.A, van Amerongen G, Norley S, Boers P, Gruters R, Osterhaus A: Decline of simian immunodeficiency virus (SIV)-specific cytotoxic T lymphocytes in the peripheral blood of long-term nonprogressing macaques infected with SIVmac32H-J5. J Infect Dis 1999; 180:1133-41.
24. Hanke T, Samuel R, Blanchard T, Neumann V, Allen T, Boyson JE et al.: Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J Virol 1999; 73:7524-32.
25. Hirsch VM, Goldstein S, Hynes NA, Elkins WR, London WT, Zack PM, Montefiori D, Johnson PR: Prolonged clinical latency and survival of macaques given a whole inactivated simian immunodeficiency virus vaccine. J Infect Dis 1994; 170:51-9.
26. Hirsch VH, Fuerst TR, Sutter G et al.: Patterns of viral replication correlate with outcome in simian immunodeficiency virus (SIV)-infected macaques: Effect of prior immunisation with a trivalent SIV vaccine in modified vaccinia virus Ankara. J Virol 1996; 70:3741-52.
27. Horton H, Vogel TU, Carter DK et al.: Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression following challenge with pathogenic SIVmac239. J Virol 2002; 76:7187-202.
28. Johnson PR: Mechanisms of protection against simian immunodeficiency virus infections. Vaccine 2002; 20:1985-7 (review).
29. Johnson RP, Glickman RL, Yang JQ, Kaur A, Dion JT, Mulligan MJ, Desrosiers RC: Induction of vigorous cytotoxic T-lymphocyte responses by live attenuated simian immunodeficiency virus. J Virol 1997; 71:7711-8.
30. Koup RA, Safrit JT, Cao Y, Andrews CA, McLeod G, Borkowsky W, Farthing C, Ho DD: Temporal association of cellular immune responses with the initial control of viremia in primary human immunodeficiency virus type 1 syndrome. J Virol 1994; 68:4650-5.
31. Lehner T, Wang Y, Cranage M, Bergmeier LA, Mitchell E, Tao L, Hall G, Dennis M, Cook N, Brookes R, Klavinskis L, Jones I, Doyle K, Ward R: Protective mucosal immunity elicited by targeted iliac lymph node immunization with a subunit SIV envelope and core vaccine in macaques. Nat Med 1996; 2:767-75.
32. Makitalo B, Lundholm P, Hinkula J, Nilsson C, Karlen K, Morner A, Sutter G, Erfle V, Heeney J, Wahren B, Biberfeld G, Thorstensson R: Enhanced cellular immunity and systemic control of SHIV infection by combined parenteral and mucosal administration of a DNA prime MVA boost vaccine regimen. J Gen Virol 2004; 85:2407-19.
33. McMichael AJ, Hanke T: HIV vaccines 1983-2003. Nat Med 2003; 9:874-80.
34. Moss B., Caroll M, Wyatt LS et al.: Host range restricted, non-replicating vaccinia virus vectors as vaccine candidates. Adv Exp Med Biol 1996; 397:7-13 (review).
35. Mwau M, Cebere I, Sutton J, Chikoti P, Winstone N, Wee EG, Beattie T, Chen YH, Dorrell L, McShane H, Schmidt C, Brooks M, Patel S, Roberts J, Conlon C, Rowland-Jones SL, Bwayo JJ, McMichael AJ, Hanke T: A human immunodeficiency virus 1 (HIV-1) clade A vaccine in clinical trials: stimulation of HIV-specific T-cell responses by DNA and recombinant modified vaccinia virus Ankara (MVA) vaccines in humans. J Gen Virol 2004; 85(Pt 4):911-9.
36. Negri D, Baroncelli S, Michelini Z et al.: Effect of vaccination with recombinant modified vaccinia virus Ankara expressing structural and regulatory genes of SIVmacJ5 on the kinetics of SIV replication in cynomolgus monkeys. J Med Primatol 2001; 30: 197-206.
37. Nilsson C, Makitalo B, Berglund P, Bex F, Liljestrom P, Sutter G, Erfle V, ten Haaft P, Heeney J, Biberfeld G, Thorstensson R: Enhanced simian immunodeficiency virus-specific immune responses in macaques induced by priming with recombinant Semliki Forest virus and boosting with modified vaccinia virus Ankara. Vaccine 2001; 19:3526-36.
38. Nixon DF, Donahoe SM, Kakimoto WM, Samuel RV, Metzner KJ, Gettie A, Hanke T, Marx PA, Connor RI: Simian immunodeficiency virus-specfic cytotoxic T lymphocytes and protection against challenge in rhesus macaques immunized with a live attenuated simian immunodeficiency virus vaccine. Virology 2000; 266:203-10.
39. Ourmanov I, Brown CR, Moss B, Carroll M, Wyatt L, Plentneva L, Goldstein S, Venzon D, Hirsch V: Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV. J Virol 2000; 74:2740-51.
40. Peyerl FW, Barouch DH, Yeh WW, Bazick HS, Kunstman J, Kunstman KJ, Wolinsky SM, Letvin NL: Simian-human immunodeficiency virus escape from cytotoxic T-lymphocyte recognition at a structurally constrained epitope. J Virol 2003; 77: 12572-8.
41. Ramirez JC, Gherardi M, Esteban M: Biology of attenuated modified vaccinia virus Ankara recombinant vector in mice: Virus fate and activation of B- and T-cell immune responses in comparison with the Western Reserve strain and advantages as a vaccine. J Virol 2000; 74:923-33.
42. Sharpe S, Polyanskaya N, Dennis M, Sutter G, Hanke T, Erfle V, Hirsch V, Cranage M: Induction of simian immunodeficiency virus (SIV)-specific CTL in rhesus macaques by vaccination with modified vaccinia virus Ankara expressing SIV transgenes: Influence of pre-existing anti-vector immunity. J Gen Virol 2001; 82:2215-23.
43. Smith JM, Amara RR, McClure HM, Patel M, Sharma S, Yi H, Chennareddi L, Herndon JG, Butera ST, Heneine W, Ellenberger DL, Parekh B, Earl PL, Wyatt LS, Moss B, Robinson HL: Multiprotein HIV type 1 clade B DNA/MVA vaccine: Construction, safety, and immunogenicity in macaques. AIDS Res Hum Retroviruses 2004; 20:654-65.
44. Stebbings R, Stott J, Almond N et al.: Mechanism of protection induced by attenuated simian immunodeficiency virus. II. Lymphocyte depletion does not abrogate protection. AIDS Res Hum 1998; 14:1187-98.
45. Stebbings R, Berry N, Stott J, Hull R, Walker B, Lines J, Elsley W, Brown S, Wade-Evans A, Davis G, Cowie J, Sethi M, Almond N: Vaccination with live attenuated simian immunodeficiency virus for 21 days protects against superinfection. Virology 2004; 330:249-60.
46. Stittelaar KJ, Gruters RA, Schutten M, van Baalen CA, van Amerongen G, Cranage M, Liljestrom P, Sutter G, Osterhaus A: Comparison of the efficacy of early versus late viral proteins in vaccination against SIV. Vaccine 2002; 20:2921-7.
47. Stott EJ, Chan WL, Mills KH, Page M, Taffs F, Cranage M, Greenaway P, Kitchin P: PrePiminary report: protection of cynomolgus macaques against simian immunodeficiency virus by fixed infected-cell vaccine. Lancet 1990; 336:1538-41.
48. Wade-Evans AM, Stott J, Hanke T, Berry N, Lines J, Sangster R, Silvera P, Walker B, MacManus S, Davis G, Cowie J, Arnold C, Hull R, Almond N: Specific proliferative T cell responses and antibodies elicited by vaccination with simian immunodeficiency virus Nef do not confer protection against virus challenge. AIDS Res Hum Retroviruses 2001; 17:1517-26.
49. Wang SW, Bertley FM, Kozlowski PA, Herrmann L, Manson K, Mazzara G, Piatak M, Johnson RP, Carville A, Mansfield K, Aldovini A: An SHIV DNA/ MVA rectal vaccination in macaques provides systemic and mucosal virus-specific responses and protection against AIDS. AIDS Res Hum Retroviruses 2004; 20:846-59.
50. Wyand MS, Manson K, Montefiori DC, Lifson JD, Johnson RP, Desrosiers RC: Protection by live, attenuated simian immunodeficiency virus against heterologous challenge. J Virol 1999; 73:8356-63.
51. Wyatt LS, Earl PL, Liu JY, Smith JM, Montefiori DC, Robinson HL, Moss B: Multiprotein HIV type 1 clade B DNA and MVA vaccines: Construction, expression, and immunogenicity in rodents of the MVA component. AIDS Res Hum Retroviruses 2004; 20:645-53.